Amicus Therapeutics, Inc. (NASDAQ:FOLD) Files J-NDA For Migalastat Market Authorization

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has revealed on Wednesday irs plans to submit a Japanese New Drug Application (J-NDA) for the commercialization of an oral medicine for Fabry disease, migalastat. J-NDA Filing Accordingly, the J-NDA will largely depend on the migalastat clinical trial results, which include a Phase 1 clinical trial evaluating the pharmacokinetics (PK) among […]

Wall Street Briefing: Agenus Inc (NASDAQ:AGEN), GoPro Inc (NASDAQ:GPRO), Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Boston, MA 07/02/2014 (wallstreetpr) – Agenus Inc (NASDAQ:AGEN) announced that its experimental drug for brain cancer showed impressive results in mid-stage study. The treatment showed that patients lived almost twice as long compared with those under standard treatments. In cases where patients only survive for less than a year under standard treatments, the experimental drug made […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Announced Effective Results In Phase 3 Trial Of Fabry Disease Treatment

Boston, MA 04/29/2014 (wallstreetpr) – Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced today that the late stage trail of its fat storage disorder treating drug showed effective results. The biopharmaceutical company, formulating treatments for orphan and rare diseases, obtained positive data for 12 and 24 months’ study of the migalastat monotherapy in patients suffering from Fabry and having […]

Amicus Therapeutics Inc. (NASDAQ:FOLD) has postpone its regulatory approval filing for the drug

Boston, MA 06/18/2013 (wallstreetpr) – The share prices of Amicus Therapeutics Inc. (NASDAQ:FOLD) had declined by 20.38 percent to close at $2.54 per share for the end of last trading session on Monday. The decline in share prices of the pharmaceutical company can be attributed to the news that Amicus Therapeutics Inc. (NASDAQ:FOLD) had decided to […]

New Fabry Drug Report Drags Amicus Down

Boston, MA 02/19/2013 (wallstreetpr) – Amicus Therapeutics, Inc. (NASDAQ:FOLD) had been working on a drug called migalastat. This drug was being developed for the treatment of a rare genetic disorder named Fabry disease which is caused when body cells buildup a certain type of fat. This fat is highly detrimental to the health in that […]